401 related articles for article (PubMed ID: 34738660)
1. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
Poole KE; Treece GM; Pearson RA; Gee AH; Bolognese MA; Brown JP; Goemaere S; Grauer A; Hanley DA; Mautalen C; Recknor C; Yang YC; Rojeski M; Libanati C; Whitmarsh T
J Bone Miner Res; 2022 Feb; 37(2):256-264. PubMed ID: 34738660
[TBL] [Abstract][Full Text] [Related]
2. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.
Keaveny TM; Crittenden DB; Bolognese MA; Genant HK; Engelke K; Oliveri B; Brown JP; Langdahl BL; Yan C; Grauer A; Libanati C
J Bone Miner Res; 2017 Sep; 32(9):1956-1962. PubMed ID: 28543940
[TBL] [Abstract][Full Text] [Related]
3. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
[TBL] [Abstract][Full Text] [Related]
4. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Brown JP; Engelke K; Keaveny TM; Chines A; Chapurlat R; Foldes AJ; Nogues X; Civitelli R; De Villiers T; Massari F; Zerbini CAF; Wang Z; Oates MK; Recknor C; Libanati C
J Bone Miner Res; 2021 Nov; 36(11):2139-2152. PubMed ID: 34190361
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
6. Romosozumab in postmenopausal women with low bone mineral density.
McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
[TBL] [Abstract][Full Text] [Related]
8. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis.
Graeff C; Campbell GM; Peña J; Borggrefe J; Padhi D; Kaufman A; Chang S; Libanati C; Glüer CC
Bone; 2015 Dec; 81():364-369. PubMed ID: 26232375
[TBL] [Abstract][Full Text] [Related]
9. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
10. Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.
Eriksen EF; Chapurlat R; Boyce RW; Shi Y; Brown JP; Horlait S; Betah D; Libanati C; Chavassieux P
J Bone Miner Res; 2022 Jan; 37(1):36-40. PubMed ID: 34633116
[TBL] [Abstract][Full Text] [Related]
11. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.
Boyce RW; Niu QT; Ominsky MS
Bone; 2017 Aug; 101():77-87. PubMed ID: 28428078
[TBL] [Abstract][Full Text] [Related]
12. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
13. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
[TBL] [Abstract][Full Text] [Related]
14. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
Cosman F; Lewiecki EM; Ebeling PR; Hesse E; Napoli N; Matsumoto T; Crittenden DB; Rojeski M; Yang W; Libanati C; Ferrari S
J Bone Miner Res; 2020 Jul; 35(7):1333-1342. PubMed ID: 32445228
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
[TBL] [Abstract][Full Text] [Related]
16. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Cosman F; Kendler DL; Langdahl BL; Leder BZ; Lewiecki EM; Miyauchi A; Rojeski M; McDermott M; Oates MK; Milmont CE; Libanati C; Ferrari S
Osteoporos Int; 2022 Jun; 33(6):1243-1256. PubMed ID: 35165774
[TBL] [Abstract][Full Text] [Related]
17. Romosozumab: A Review in Postmenopausal Osteoporosis.
Paik J; Scott LJ
Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
[TBL] [Abstract][Full Text] [Related]
18. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
Nealy KL; Harris KB
Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
[TBL] [Abstract][Full Text] [Related]
19. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
